Touchstone
Last syncNov 1, 2026, 6:55 PM ET

BMRN

Biomarin Pharmaceutical Inc Health Care Pharmaceutical Preparations Russell 3000
$58.51Close $11.3BMarket cap $49.67 – $70.2452-week range Nov 2, 2026Next report · after the close

Highlights

Cautions

  • Not in an uptrend 4 of 8 trend conditions
  • Earnings shrinking EPS −81% year on year
  • Results soon Nov 2, 2026, in 1 day

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026
Off 12-month high 17%
1wk up 4.6% price change
1mo down 2.5% price change
12-month return up 13% market up 11% · its own up 2%
F-score 5 / 9 Mixed
Altman Z 5.61 Low risk
P/E 32.2× price / earnings
PEG — P/E / EPS growth
P/B 1.8× price / book
Earnings yield up 3.9% EBIT / enterprise value
Cheaper than 68% of the market · cheap
Revenue growth up 13% year on year
EPS growth down 81% latest quarter · -38 pts
Sales growth up 20% latest quarter · +17 pts
ROE up 6% return on equity
Free cash margin up 23% $725.0M FCF
D/E 0.10 long-term debt / equity
Net debt / EBITDA -1.5× net cash
Interest cover —EBIT / interest
Piotroski tests
  • profitability slipped from last year
  • short-term liquidity weakened
  • issued more shares
  • gross margin narrowed
  • profitable on its assets
  • generating cash from operations
  • profits backed by cash
  • reduced long-term debt
  • assets working harder

Trade setup

ATR% 2.7% $1.61 a day · 2×ATR $55.30
RS 51 / 99 vs the universe
Trend 4 / 8 trend template
Relative volume 1.1× vs 50-day average
Up/down volume 0.71 50 sessions
Implied move — no option chain · report Nov 2, 2026
Trend template · 4 of 8
  • Price above the 150 and 200-day averages: passes
  • 150-day average above the 200-day: passes
  • 200-day average rising for a month: fails
  • 50-day average above the 150 and 200-day: passes
  • Price above the 50-day average: fails
  • At least 30% above the 52-week low: fails
  • Within 25% of the 52-week high: passes
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Gross margin narrowing Gross margin fell from 79.7% to 77.7%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported Oct 6, 2026
Results reaction Oct 6, 2026-4% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $3.2B +13% on FY2024
$0 $5B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $1.9B FY2021 · $1.8B FY2022 · $2.1B FY2023 · $2.4B FY2024 · $2.9B FY2025 · $3.2B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $348.9M -18% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $854.0M FY2021 · -$64.1M FY2022 · $141.6M FY2023 · $167.6M FY2024 · $426.9M FY2025 · $348.9M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $725.0M +49% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$28.9M FY2021 · $209.0M FY2022 · $54.9M FY2023 · $62.6M FY2024 · $487.4M FY2025 · $725.0M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 78%
  • Net 11%
  • Free cash 23%
0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 72% · Net 46% · Free cash -2% FY2021 · Gross 75% · Net -3% · Free cash 11% FY2022 · Gross 76% · Net 7% · Free cash 3% FY2023 · Gross 78% · Net 7% · Free cash 3% FY2024 · Gross 80% · Net 15% · Free cash 17% FY2025 · Gross 78% · Net 11% · Free cash 23%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $714.5M net cash
  • Cash
  • Long-term debt
$0 $2B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $649.2M · Long-term debt $1.1B FY2021 · Cash $587.3M · Long-term debt $1.1B FY2022 · Cash $724.5M · Long-term debt $1.1B FY2023 · Cash $755.1M · Long-term debt $1.1B FY2024 · Cash $942.8M · Long-term debt $600.0M FY2025 · Cash $1.3B · Long-term debt $597.2M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 192.30m +5.8% since FY2020
192.30m 181.74m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 181.74m FY2021 · 183.91m FY2022 · 186.25m FY2023 · 188.60m FY2024 · 190.76m FY2025 · 192.30m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $1.9B $1.8B $2.1B $2.4B $2.9B $3.2B
Gross margin 72% 75% 76% 78% 80% 78%
Operating income -$43.4M -$82.3M $161.0M $185.8M $484.2M $409.5M
Net income $854.0M -$64.1M $141.6M $167.6M $426.9M $348.9M
Net margin 46% -3% 7% 7% 15% 11%
Earnings per share $4.46 -$0.35 $0.75 $0.87 $2.17 $1.77
Free cash flow -$28.9M $209.0M $54.9M $62.6M $487.4M $725.0M
Free cash margin -2% 11% 3% 3% 17% 23%
Cash $649.2M $587.3M $724.5M $755.1M $942.8M $1.3B
Long-term debt $1.1B $1.1B $1.1B $1.1B $600.0M $597.2M
Shareholders' equity $4.1B $4.3B $4.6B $5.0B $5.7B $6.1B
Shares outstanding 181.74m 183.91m 186.25m 188.60m 190.76m 192.30m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 6, 2026 Quarterly ↗ Jun 30, 2026 37d
May 5, 2026 Quarterly ↗ Mar 31, 2026 35d
Feb 26, 2026 Annual ↗ Dec 31, 2025 57d
Oct 28, 2025 Quarterly ↗ Sep 30, 2025 28d
Aug 5, 2025 Quarterly ↗ Jun 30, 2025 36d
May 2, 2025 Quarterly ↗ Mar 31, 2025 32d
Feb 24, 2025 Annual ↗ Dec 31, 2024 55d
Oct 31, 2024 Quarterly ↗ Sep 30, 2024 31d
Aug 5, 2024 Quarterly ↗ Jun 30, 2024 36d
Apr 26, 2024 Quarterly ↗ Mar 31, 2024 26d
Feb 26, 2024 Annual ↗ Dec 31, 2023 57d
Nov 2, 2023 Quarterly ↗ Sep 30, 2023 33d

Current reports

FiledDisclosed
Oct 6, 2026 Results ↗
Sep 30, 2026 Material agreement ↗
Sep 15, 2026 Other events ↗
Sep 14, 2026 Director or officer change ↗
Sep 1, 2026 Other events ↗
Aug 31, 2026 Material agreement · Regulation FD ↗
Aug 18, 2026 Material agreement · Regulation FD ↗
Aug 6, 2026 Results ↗
Jun 4, 2026 Director or officer change · Shareholder vote ↗
May 4, 2026 Results ↗
Apr 27, 2026 Material agreement · Acquisition or disposal · New obligation · Regulation FD ↗
Apr 23, 2026 Other events ↗